Memantine: A therapeutic drug for Alzheimer's disease and the comparison with MK-801

Folia Pharmacologica Japonica

Volumn 124, Issue 3, 2004, Pages 145-151

  Kato, Takeshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Magnesium ion; MK 801; Therapy

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; DIZOCILPINE; GLUTAMIC ACID; ION CHANNEL; KETAMINE; MAGNESIUM ION; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; BRAIN CORTEX; DRUG BINDING; ELECTRIC POTENTIAL; HUMAN; ISCHEMIA; NERVE CELL NECROSIS; REVIEW; SCHIZOPHRENIA;

ALZHEIMER DISEASE; BINDING SITES; CONTROLLED CLINICAL TRIALS; DIZOCILPINE MALEATE; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATES; HUMANS; ION CHANNELS; MAGNESIUM; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 4644335339     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.145     Document Type: Review

References (13)

1. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res. 2000;2:85-97.
2. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18 Suppl 1: S23-S32.
3. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 1999;38:735-767.
4. Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate- evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther. 1992;263:717-724.
5. Ahmed MM, Hoshino H, Chikuma T, Yamada M, Kato T. Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated Alzheimer's disease model. Neuroscience. 2004;126:639-649.
6. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515-1518.
7. Kim SH, Price MT, Olney JW, Farber NB. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol Psychiatry. 1999;4:344-352.
8. Farber NB, Jiang X-P, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7:726-733.
9. Ahmed MM, Yamamoto M, Chikuma T, Rahman MM, Kato T. Dose-dependent effect of MK-801 on the levels of neuropeptides processing enzymes in rat brain regions. Neurosci Res. 2003;47:177-189.
10. Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm. Suppl 1995;46 (Parkinsons Disease: Experimental Models and Therapy): 97-105.
11. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 1993;32:1337-1350.
12. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
13. Jarvis B, Figgitt D. Memantine. Drugs Aging. 2003;20:465-476.